Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 303

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Open access
Kulke, Matthew H., Hörsch, Dieter, Caplin, Martyn E., Anthony, Lowell B., Bergsland, Emily, Öberg, Kjell, Welin, Staffan, Warner, Richard R.P., Lombard-Bohas, Catherine, Kunz, Pamela L., Grande, Enrique, Valle, Juan W., Fleming, Douglas, Lapuerta, Pablo, Banks, Phillip, Jackson, Shanna, Zambrowicz, Brian, Sands, Arthur T., Pavel, Marianne·2017·Journal of Clinical Oncology

Abstract

Purpose: Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods: Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results: Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were –0.81 for telotristat ethyl 250 mg ( P < .001) and ‒0.69 for telotristat ethyl 500 mg ( P < .001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were –0.9, –1.7, and –2.1, respectively. Responses, predefined as a BM frequency reduction ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 ( P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion: Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.69.2780

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 303

Metadata

Authors
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T., & Pavel, M.
Venue
Journal of Clinical Oncology
Published
2017-01-01
Volume
35
Issue
1
Pages
14-23
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2547287898
Cited by
303
References
21
FWCI
30.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. https://app.cochat.ai/papers/10.1200/jco.2016.69.2780
The paper
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T., & Pavel, M. (2017). Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.69.2780

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.